A rare case of uterine leiomyosarcoma: A case report

被引:12
作者
Vellanki V. [1 ]
Rao M. [1 ]
Sunkavalli C. [1 ]
Chinamotu R. [1 ]
Kaja S. [1 ]
机构
[1] Department of Obstetrics and Gynaecology, Kamineni Institute of Medical Sciences Sreepuram, Narketpally, Nalgonda - 508254, Andhra Pradesh
关键词
Leiomyoma; Leiomyosarcoma; Tumor Giant Cell; Uterine Fibroid; Uterine Sarcoma;
D O I
10.1186/1752-1947-4-222
中图分类号
学科分类号
摘要
Introduction. Malignant change in a leiomyoma or uterine fibroid is termed leiomyosarcoma. It arises from smooth muscle of the uterus and is a rare tumor that accounts for 2% to 5% of all uterine malignancies. Very few cases are reported in the literature. Our patient did not have any history of genital bleeding, which is the usual presentation in uterine sarcoma. We report an original case report of an unusual presentation of this rare tumor arising from the uterus. Case presentation. A 40-year-old nulliparous woman of South Indian origin presented with a mass in her abdomen for one year with a rapid increase in size over the previous three months. Tumor marker CA-125 was raised, and a computed tomography scan showed a mass arising from the pelvis. An exploratory laparotomy was performed and the histopathology report confirmed the diagnosis of uterine leiomyosarcoma. Conclusion. Because of their rarity, uterine sarcomas are not suitable for screening. Diagnosis is by histopathologic examination and surgery is the only treatment. The prognosis for women with uterine sarcoma primarily depends on the extent of disease at the time of diagnosis and the mitotic index. © 2010Vellanki et al; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2010 Vellanki et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 6 条
[1]  
Forney J.P., Buschbaum H.J., Classifying staging and treating uterine sarcomas, Contemporary Ob Gyn, 18, 3, (1981)
[2]  
Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., Van Leeuwen F.E., Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres ALERT Group Assessment of Liver and Endometrial Cancer Risk Following Tamoxifen, Lancet, 356, pp. 881-887, (2000)
[3]  
Wickerham D.L., Fisher B., Wolmark N., Bryant J., Costantino J., Bernstein L., Runowicz C.D., Association of tamoxifen and uterine sarcoma, J Clin Oncol, 20, pp. 2758-2760, (2002)
[4]  
Major F.J., Blessing J.A., Silverberg S.G., Morrow C.P., Creasmam W.T., Currie J.L., Yordan E., Brady M.F., Prognostic factors in early stage uterine sarcoma. A Gynaecologic Oncology group study, Cancer, 71, 4, pp. 1702-1709, (1993)
[5]  
Evans H.L., Chawla S.P., Simpson C., Finn K.P., Smooth muscle neoplasms of the uterus other than ordinary leiomyoma. A study of 46 cases, with emphasis on diagnostic criteria and prognostic factors, Cancer, 62, 10, pp. 2239-2247, (1988)
[6]  
Piver M.S., Lele S.B., Marchetti D.L., Emrich L.J., Effect of adjuvant chemotherapy on time to recurrence and survival of stage 1 uterine sarcomas, J Surg Oncol, 38, 4, pp. 233-239, (1988)